Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies...
JP Morgan analyst Brian Cheng downgrades Precigen (NASDAQ:PGEN) from Neutral to Underweight.
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...
JMP Securities analyst Jason Butler reiterates Precigen (NASDAQ:PGEN) with a Market Outperform and maintains $14 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price t...
– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen p...
Full Year 2023 Financial Results Compared to Prior Year PeriodResearch and development expenses increased $1.4 million, or 3.1%...
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...
